ProxAI accelerates drug discovery for hard-to-drug targets by engineering custom modulator proteins that inhibit key protein-protein interactions or induce degradation. All validated in cells.
Addressing the structural and functional bottlenecks holding back drug discovery pipelines from moving forward.
The problem:
Most
PROTAC discovery programs rely on just a few E3 ligases, all
expressed throughout the body, causing side effects.
The problem:
Small-molecule ligands often cross-react with closely related
proteins in the same family, limiting selectivity.
The problem:
Many
disease-driving proteins lack the defined pockets needed for small
molecules to block broad, flat protein–protein interfaces.
The problem:
Your
target has five functional domains. You need to study one. A
knockout eliminates them all.
Binding modules and constructs are designed from structure and delivered with cellular validation.
Target-Recognition Protein module
A target-recognition protein is engineered to engage a chosen domain surface and designed to sterically block an extended protein–protein interface.
Both Halves, One Construct
A target-recognition protein and an E3 ligase binder are designed and connected by a linker to form a bioPROTAC that induces degradation of your target protein.
Begin with a non-confidential overview of your target and program goals, at no cost and no commitment.
Schedule your target reviewA connected modulator design, protein engineering, and cellular-validation workflow.
Share your target, its biology, and desired modulation mechanism at no cost, no obligation. Expect a concrete design brief within the week.
We computationally design and rank modulator candidates against your target's interface. Modulators are ready for cell validation.
We perform functional binding or degradation assays in physiologically relevant cell lines.
Review your complete data package through our secured portal, including: sequences, structural models, cell validation results, and engineering documentation.
Start with a non-confidential target description and program objective at no cost, no obligation.
Start My Target ReviewTwo de novo designs against flat, previously undruggable interfaces. Each from a single design round and confirmed in live cells.
A single round of AI-generated de novo peptides against the CDC20 D-box degron interface more than doubled the cell-death response of Apcin, a known small-molecule CDC20 inhibitor, in HeLa cells.
A ProxAI minibinder selectively intercepts an undruggable kinase-effector interface in immune cells, leaving the target's remaining functions intact. No natural template, one design round, in under three months.
In collaboration with an academic partner laboratory, we are evaluating 6,000 de novo bioPROTAC variants against two undisclosed, functionally linked intracellular targets in a single pooled lentiviral CRISPR screen. Targets and biological context withheld under NDA.
Physical lab operations embedded at IRCM in Montreal.
Experimental prioritization of computationally designed candidates.
Confirms inhibition or degradation activity directly in cells.
A non-confidential target name or class, the biological outcome you want, and any constraint we should design around (E3 preference, cell line, delivery format). No sequences or coordinates at this stage.
Intracellular and extracellular protein targets where a structure or a confident predicted model exists.
Every target-binding module ships with target engagement confirmed in a mammalian cell line by flow cytometry and PLA.
Binder sequence(s) in FASTA, a structural model of the predicted ternary complex (PDB), raw and analyzed validation data, expression and stability notes, and a written engineering rationale for the epitope and geometry chosen. Data is fully accessible through our secure portal.
The initial form is pre-NDA. Request an NDA in the form and we return a mutual NDA within two business days before any structure or sequence is shared.
Book a 30-minute scoping call to talk through your target, E3 strategy, and the right engineering path.
Book a meetingOpens Google Calendar · 30 min · Pre-NDA
